Deleobuvir sodium - CAS 1370023-80-5

Deleobuvir sodium is the salt form of Deleobuvir, also known as BI207127, a non-nucleoside hepatitis C virus NS5B polymerase inhibitor for the treatment of hepatitis C. Deleobuvir was tested in combination regimens with pegylated interferon and ribavirin, and in interferon-free regimens with other direct-acting antiviral agents including faldaprevir. Deleobuvir showed that a triple combination of deleobuvir, faldaprevir, and ribavirin performed well in HCV genotype 1b patients. Efficacy fell below 50%, however, for dual regimens without ribavirin and for genotype 1a patients. In December 2013, deleobuvir was discontinued since recent findings from phase III trials did not suggest sufficient efficacy.

Others, Endogenous Metabolite

Others, Metabolism

1369938

C34H32BrN6NaO3

675.56

[Na+].Cn1c(c(C2CCCC2)c2ccc(cc12)C(=O)NC1(CCC1)c1nc2ccc(\C=C\C([O-])=O)cc2n1C)-c1ncc(Br)cn1

-20°C

Ice Packs

Small Compound